Combating a Global Pandemic of Weak, Adulterated, and Fake Drugs

Authors

  • Menghis Bairu Founder and CEO of Serenus Biotherapeutics

DOI:

https://doi.org/10.5912/jcb712

Keywords:

falsified drugs, Good Laboratory Practices, regulation

Abstract

Whether it’s willful counterfeiting, sloppy manufacturing processes, or neglectful handing of drugs in the global supply chain, recent studies suggest the problem of weakened, adulterated, and fake drugs is a growing global issue with deadly consequences. In Africa, the lack of access to innovative drugs makes the population vulnerable to counterfeits and inefficacious copies of medicines that are much needed. This humanitarian crisis rests on policymakers’ steadfastness in each country to ensure the authenticity of the drug supply. Among the steps that should be taken is the restriction of the sale of drugs to pharmacies and hospitals and the prohibition of their sale through street vendors and open markets. There is also an urgent need for post-importation testing to ensure drugs actually contain their active ingredients in adequate strength before they are sold.  These are necessary parts of a needed comprehensive approach to combating the importation of counterfeit, weakened, and adulterated drugs. Countries have it within their power to protect their populations, ensure the integrity of medications, and restore trust in their healthcare systems.

Author Biography

Menghis Bairu, Founder and CEO of Serenus Biotherapeutics

Dr. Bairu is the former Executive Vice President, Chief Medical Officer, and Head of Global Development of Elan Corporation. He also served as Elan’s General Manager, was the head of Elan International, and has broad international experience in the United States, Europe, Latin America, South East Asia, the Middle East, and Africa. Prior to that, he worked for several leading biopharmaceutical companies including Genentech, Johnson & Johnson, and served on the board of OneWorld Health, a not-for-profit pharmaceutical company funded by the Bill and Melinda Gates Foundation. Dr. Bairu is also an author and lectures widely on global health and biopharmaceutical issues, particularly in emerging markets.

Downloads

Published

2015-07-01

Issue

Section

Commentary